Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Blood (2023) 142 (Supplement 1): 4551.

https://doi.org/10.1182/blood-2023-180945

Published: 2023

Journal Articles

Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 ( FGFR1 ) Rearrangement (MLN FGFR1 ): A US Real-World Retrospective Cohort Study

Shreekant Parasuraman, Anna Teschemaker, Jonathan K. Kish, Kristin M. Savill, Philomena Colucci

Blood (2022) 140 (Supplement 1): 6854–6855.

https://doi.org/10.1182/blood-2022-162320

Published: 2022

Journal Articles

FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 ( FGFR1 ) Rearrangement (MLN FGFR1 ): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients

Srdan Verstovsek, Jason Gotlib, Alessandro M. Vannucchi, Alessandro Rambaldi, Andreas Reiter, William Shomali, Tracy I. George, Jay L. Patel, Philomena Colucci, Huiling Zhen, Natalia Oliveira, Jean-Jacques Kiladjian

Blood (2022) 140 (Supplement 1): 3980–3982.

https://doi.org/10.1182/blood-2022-163099

Published: 2022

Journal Articles

A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1 )

Jason Gotlib, Jean-Jacques Kiladjian, Alessandro Vannucchi, Alessandro Rambaldi, Andreas Reiter, William Shomali, Tracy I. George, Jay L. Patel, Philomena Colucci, Chris Walker, Huiling Zhen, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 385.

https://doi.org/10.1182/blood-2021-148103

Published: 2021

Journal Articles

Risk of Hemorrhage in Patients with Polycythemia Vera Exposed to Aspirin in Combination with Anticoagulants: Results of a Prospective, Multicenter, Observational Cohort Study (REVEAL)

Jeffrey I. Zwicker, MD, David S. Lessen, MD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, Michael R. Grunwald, MD

Blood (2019) 134 (Supplement_1): 168.

https://doi.org/10.1182/blood-2019-123835

Published: 2019

Journal Articles

Persistence of Ruxolitinib Treatment in Patients with Myelofibrosis at Community Oncology Practices in the United States-Contemporary Data

Jingbo Yu, PhD, Jonathan K. Kish, PhD MPH, Dilan Paranagama, PhD, Philomena Colucci, DO, MS

Blood (2019) 134 (Supplement_1): 5385.

https://doi.org/10.1182/blood-2019-123833

Published: 2019

Journal Articles

REVEAL: Characteristics of Patients with Polycythemia Vera Who Were Diagnosed within 6 Months of Enrollment

Aaron T. Gerds, MD MS, Ivy Altomare, MD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, John M Burke, MD

Blood (2019) 134 (Supplement_1): 5370.

https://doi.org/10.1182/blood-2019-121386

Published: 2019

Journal Articles

Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea

Ivy Altomare, MD, Anna Nguyen, PharmD, MPH, Shreekant Parasuraman, BPharm, PhD, Dilan Paranagama, PhD, Jonathan K. Kish, PhD MPH, Kevin Lord, PhD MHS, Philomena Colucci, DO, MS

Blood (2019) 134 (Supplement_1): 4192.

https://doi.org/10.1182/blood-2019-127442

Published: 2019

Journal Articles

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2948.

https://doi.org/10.1182/blood-2019-124343

Published: 2019

Journal Articles

Patient-Reported Outcomes (PRO) Data from Patients (Pts) with Essential Thrombocythemia (ET) Enrolled in the MOST Study

Ellen K. Ritchie, MD, Anas Al-Janadi, MD, Philomena Colucci, DO, MS, Patricia Kalafut, PhD, Dilan Paranagama, PhD, Ruben A. Mesa, MD

Blood (2019) 134 (Supplement_1): 1665.

https://doi.org/10.1182/blood-2019-124527

Published: 2019

Journal Articles

Disease and Clinical Characteristics of Patients with Myelofibrosis Enrolled in the MOST Study

Aaron T. Gerds, MD MS, Roger M. Lyons, MD, Philomena Colucci, DO, MS, Patricia Kalafut, PhD, Dilan Paranagama, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4190.

https://doi.org/10.1182/blood-2019-122441

Published: 2019

Journal Articles

Disease and Clinical Characteristics of Patients with Essential Thrombocythemia Enrolled in the MOST Study

Abdulraheem Yacoub, MD, Roger M. Lyons, MD, Srdan Verstovsek, MD PhD, Ryan Shao, MD, David Tin Chu, MD, Apurv Agrawal, MD, Smitha Sivaraman, PhD, Philomena Colucci, DO, MS, Peter Yao, John Mascarenhas, MD

Blood (2018) 132 (Supplement 1): 4306.

https://doi.org/10.1182/blood-2018-99-112183

Published: 2018

Journal Articles

Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United States

Srdan Verstovsek, MD PhD, Jingbo Yu, PhD, Jonathan K. Kish, PhD MPH, Dilan Chamikara Paranagama, PhD, Jill Kaufman, Jessica Chung, PhD MPH, Michael R. Grunwald, MD, Philomena Colucci, DO, MS, Ruben A. Mesa, MD FACP

Blood (2018) 132 (Supplement 1): 1765.

https://doi.org/10.1182/blood-2018-99-115294

Published: 2018

Journal Articles

Characteristics Associated with Hydroxyurea Treatment Change in Patients with Polycythemia Vera: An Analysis from the Reveal Study

Anas Al-Janadi, MD, Ruben A. Mesa, MD FACP, Philomena Colucci, DO, MS, Shreekant Parasuraman, BPharm, PhD, Dilan Chamikara Paranagama, PhD, Michael Richard Grunwald, MD

Blood (2018) 132 (Supplement 1): 1770.

https://doi.org/10.1182/blood-2018-99-111986

Published: 2018

Journal Articles

Disease Characteristics of Minority Patient Populations with Polycythemia Vera: An Analysis from the Reveal Study

Ivy Altomare, MD, Philomena Colucci, DO, MS, Shreekant Parasuraman, BPharm, PhD, Dilan Chamikara Paranagama, PhD, Anas Al-Janadi, MD

Blood (2018) 132 (Supplement 1): 4735.

https://doi.org/10.1182/blood-2018-99-112530

Published: 2018

Journal Articles

Correlation between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal Study

Ivy Altomare, MD, Aaron T. Gerds, MDMS, David Lessen, MD, Philomena Colucci, DO, MS, Shreekant Parasuraman, BPharm, PhD, Dilan Chamikara Paranagama, PhD, Ruben A. Mesa, MD FACP

Blood (2018) 132 (Supplement 1): 2259.

https://doi.org/10.1182/blood-2018-99-112937

Published: 2018

Journal Articles

Real-World Patterns of First-Line Hydroxyurea Treatment Among Patients with Essential Thrombocythemia in US Community Oncology Practices

Jingbo Yu, PhD, Philomena Colucci, DO, MS, Dilan Chamikara Paranagama, PhD, Smitha Sivaraman, PhD, Pavel Atanasov, Becky Hanna, Jackson Tang, Shreekant V. Parasuraman, BPharm, PhD

Blood (2017) 130 (Supplement 1): 4203.

https://doi.org/10.1182/blood.V130.Suppl_1.4203.4203

Published: 2017

Journal Articles

Patient-Reported Symptom Burden and Peripheral Blood Counts Among Patients with Polycythemia Vera: An Analysis from the Reveal Study

Michael Richard Grunwald, MD, John M. Burke, MD, David J Kuter, MD DPhil, Aaron T. Gerds, MDMS, Brady Lee Stein, MD MHS, Michael R. Savona, MD, Mark A. Walshauser, MD, Ahmad B. Naim, MD, Philomena Colucci, DO, MS, Dilan Chamikara Paranagama, PhD, Ruben A Mesa, MD

Blood (2017) 130 (Supplement 1): 2924.

https://doi.org/10.1182/blood.V130.Suppl_1.2924.2924

Published: 2017

Journal Articles

Examining the Treatment Patterns and Blood Counts Among Patients with Polycythemia Vera Treated with Hydroxyurea in the United States: An Analysis from the Reveal Study

Michael Richard Grunwald, MD, Ivy Altomare, MD, John M. Burke, MD, Aaron T. Gerds, MDMS, Mark A. Walshauser, MD, Michael R. Savona, MD, David J Kuter, MD DPhil, Brady Lee Stein, MD MHS, Stephen Oh, MD PhD, Philomena Colucci, DO, MS, Ahmad B. Naim, MD, Dilan Chamikara Paranagama, PhD, Ruben A Mesa, MD

Blood (2017) 130 (Supplement 1): 1633.

https://doi.org/10.1182/blood.V130.Suppl_1.1633.1633

Published: 2017

Journal Articles

Characteristics of 809 Patients with Essential Thrombocythemia in Real-World Clinical Practice: A Chart Review Study in the United States

Jingbo Yu, PhD, Philomena Colucci, DO, MS, Dilan Chamikara Paranagama, PhD, Smitha Sivaraman, PhD, Pavel Atanasov, Becky Hanna, Jackson Tang, Shreekant V. Parasuraman, BPharm, PhD

Blood (2017) 130 (Supplement 1): 1636.

https://doi.org/10.1182/blood.V130.Suppl_1.1636.1636

Published: 2017

NARROW

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 ( FGFR1 ) Rearrangement (MLN FGFR1 ): A US Real-World Retrospective Cohort Study

FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 ( FGFR1 ) Rearrangement (MLN FGFR1 ): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients

A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1 )

Risk of Hemorrhage in Patients with Polycythemia Vera Exposed to Aspirin in Combination with Anticoagulants: Results of a Prospective, Multicenter, Observational Cohort Study (REVEAL)

Persistence of Ruxolitinib Treatment in Patients with Myelofibrosis at Community Oncology Practices in the United States-Contemporary Data

REVEAL: Characteristics of Patients with Polycythemia Vera Who Were Diagnosed within 6 Months of Enrollment

Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Patient-Reported Outcomes (PRO) Data from Patients (Pts) with Essential Thrombocythemia (ET) Enrolled in the MOST Study

Disease and Clinical Characteristics of Patients with Myelofibrosis Enrolled in the MOST Study

Disease and Clinical Characteristics of Patients with Essential Thrombocythemia Enrolled in the MOST Study

Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United States

Characteristics Associated with Hydroxyurea Treatment Change in Patients with Polycythemia Vera: An Analysis from the Reveal Study

Disease Characteristics of Minority Patient Populations with Polycythemia Vera: An Analysis from the Reveal Study

Correlation between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal Study

Real-World Patterns of First-Line Hydroxyurea Treatment Among Patients with Essential Thrombocythemia in US Community Oncology Practices

Patient-Reported Symptom Burden and Peripheral Blood Counts Among Patients with Polycythemia Vera: An Analysis from the Reveal Study

Examining the Treatment Patterns and Blood Counts Among Patients with Polycythemia Vera Treated with Hydroxyurea in the United States: An Analysis from the Reveal Study

Characteristics of 809 Patients with Essential Thrombocythemia in Real-World Clinical Practice: A Chart Review Study in the United States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only